NO DIFFERENCES IN GI BLEEDING RISK BETWEEN CLOPIDOGREL-, TICAGRELOR- OR PRASUGREL-BASED DUAL ANTIPLATELET THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION

(1) Hospital Clínico Lozano Blesa,Zaragoza,Spain

(2) University of Zaragoza University Hospital Dept. of Medicine-Gastroenterology,Zaragoza,Spain

(3) CIBERehd,Madrid,Spain



This item was part of UEG Week 2018

This item can be cited as: United European Gastroenterology Journal 2018; 6 (Supplement 1)